Raynaud's phenomenon{lozenge, open}{lozenge, open}Pour citer cet article, utiliser ce titre en anglais et sa référence dans le même volume de Joint Bone Spine.;Phénomène de Raynaud

Revue du Rhumatisme (Edition Francaise)

Volumn 74, Issue 1, 2007, Pages

  Gayraud, Martine ^a  

^a INSTITUT MUTUALISTE MONTSOURIS   (France)

Author keywords

Calcium channel antagonists; Raynaud's phenomenon; Scleroderma

Indexed keywords

EID: 33846598770     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rhum.2006.07.002     Document Type: Short Survey

References (55)

1. Carpentier P.H. Définition et épidémiologie des acrosyndromes vasculaires. Rev. Prat. 46 (1998) 1641-1646
2. Block J.A., and Sequeira W. Raynaud's phenomenon. Lancet 357 (2001) 2042-2048
3. Wigley F.M. Raynaud's phenomenon. N. Engl. J. Med. 347 (2002) 1001-1008
4. O'Keefe S.T., Tsapatsaris N.P., and Beetham W.P. Increased prevalence of migraine and chest pain in patients with primary Raynaud's disease. Ann. Intern. Med. 116 (1992) 985-989
5. Suter L.G., Murabito J.M., Felson D.T., and Fraenkel L. The incidence and natural history of Raynaud's phenomenon in the community. Arthritis Rheum. 52 (2005) 1259-1263
6. Olsen N., and Nielsen S.L. Prevalence of primary Raynaud phenomena in young females. Scand. J. Clin. Lab. Invest. 37 (1978) 761-764
7. Jones G.T., Herrick A.L., Woodham S.E., Baildam E., Macfarlane G.I., and Silman A.J. Occurrence of Raynaud's phenomenon in children aged 12-15 years. Arthritis Rheum. 48 (2003) 3518-3523
8. Herrick A.L. Pathogenesis of Raynaud's phenomenon. Rheumatol. 44 (2005) 587-596
9. Flavahan N.A., Flavahan S., Mitra S., and Chotani M.A. The vasculopathy of Raynaud's phenomenon and scleroderma. Rheum. Dis. Clin. N. Am. 29 (2003) 275-291
10. Mayes M.D. Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum. 48 (2003) 1190-1199
11. Furspan P.B., Chatterjee S., Mayes M.D., and Freedman R.R. Cooling-induced contraction and protein tyrosine kinase activity of isolated arterioles in secondary Raynaud's phenomenon. Rheumatology 44 (2005) 488-494
12. Furspan P.B., Chatterjee S., and Freedman R.R. Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease. Arthritis Rheum. 50 (2004) 1578-1585
13. Generini S., Seibold J.R., and Matucci-Cerinic M. Estrogens and neuropeptides in Raynaud's phenomenon. Rheum. Dis. Clin. N. Am. 31 (2005) 177-186
14. Planchon B., Pistorius M.A., Beurrier P., and de Faucal P. Primary's Raynaud's phenomenon. Age of onset and pathogenesis in a prospective study of 424 patients. Angiology 45 (1994) 677-686
15. Ziegler S., Brunner M., Eigenbauer E., and Minar E. Long-term outcome of primary's Raynaud's phenomenon and its conversion to connective tissue disease: a 12-year retrospective patient analysis. Scand. J. Rheumatol. 32 (2003) 343-347
16. Manmarino E., Pasqualini L., Fedeli F., Scricciolo V., and Innocente S. Nailfold capillaroscopy in the screening and diagnosis of Raynaud's phenomenon. Angiology 45 (1994) 37-42
17. Cutolo M., Grassi W., and Matucci-Cerinic M. Raynaud's phenomenon and the role of capillaroscopy. Arthritis Rheum. 48 (2003) 3023-3030
18. Hatron P.Y., Frimat P., and Hachulla E. Phénomènes de Raynaud d'origine professionnelle. Rev. Prat. 48 (1998) 1653-1658
19. Boillat M.A., and Thorens B. Acrosyndromes et maladies professionnelles : épidémiologie et prévention de la maladie des engins vibrants. Rev. Med. Suisse Romande 112 (1992) 405-407
20. Hachulla E., Gillard J., and Duquesnoy B. Clinique du syndrome de la traversée cervicothoracobrachiale. Rev. Med. Int. 5 Suppl (1999) 464-467
21. Belch J.J., and Ho M. Pharmacotherapy of Raynaud's phenomenon. Drugs 52 (1996) 682-695
22. Allanore Y., and Kahan A. Treatment of systemic sclerosis. Joint Bone Spine 73 (2006) 363-368
23. Allanore Y., Borderie D., Lemarechal H., Ekindjian O.G., and Kahan A. Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis. Am. J. Med. 116 (2004) 595-600
24. Thompson A.E., and Pope J.E. Calcium channel blockers for primary's Raynaud's phenomenon: a metaanalysis. Rheumatol. 44 (2005) 145-150
25. Raynaud's Treatment Study Investigators. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud's phenomenon. Results from a randomized clinical trial with 1-year follow-up. Arch. Intern. Med. 160 (2000) 1101-1108
26. Thompson A.E., Shea B., Welch V., Fenlon D., and Pope J.E. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum. 44 (2001) 1841-1847
27. Hummers L.K., and Wigley F.M. Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma. Rheum. Dis. Clin. N. Am. 29 (2003) 293-313
28. The L.S., Manning J., Moore T., Tully M.P., O'Reilly D., and Jayson M.I.V. Sustained-release transdermal glyceryl trinitrate patches as treatment for primary and secondary Raynaud's phenomenon. Br. J. Rheumatol. 34 (1995) 636-641
29. Wise R.A., Wigley F.M., White B., Leatherman G., Zhong J., Krasa H., et al. Efficacy and tolerability of a selective α2c-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients. Arthritis Rheum. 50 (2004) 3994-4001
30. Le Quintrec P., and Lefebvre M.L. Double-blind placebo-controlled trial of buflomedil in the treatment of Raynaud's phenomenon: six-month follow-up. Angiology 42 (1991) 289-295
31. Davinroy M., and Mosnier M. Évaluation clinique en double-insu du naftidrofuryl dans le phénomène de Raynaud. Sem. Hop. Paris 69 (1993) 1322-1326
32. Wigley F.M., Wise R.A., Seibold J.R., McCloskey D.A., Kujala G., Medsger Jr. T.A., et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. Ann. Intern. Med. 120 (1994) 199-206
33. Torlay H.I., Madock R., Capell H.A., Brouwer R.M., Maddison P.J., Black C.M., et al. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann. Rheum. Dis. 50 (1991) 800-804
34. Scorza R., Caronni M., Mascagni B., Berruti V., Bazzi S., Micaleff E., et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized controlled study. Clin. Exp. Rheumatol. 19 (2001) 503-508
35. Rademaker M., Cooke E.D., Almond N.E., Beacham J.A., Smith R.E., Mant T.G., et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomized study. BMJ 298 (1989) 561-564
36. Wigley F.M., Korn J.H., Czuka M.E., Medsger T.A., Rothfield N.F., Ellman M., et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis. Arthritis Rheum. 41 (1998) 670-677
37. Vayssairat M. Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Multicenter Group for the Study of Vascular Acrosyndromes. J. Rheumatol. 26 (1999) 2173-2178
38. Humbert M., Sitbon O., and Simonneau G. Drug therapy: treatment of pulmonary hypertension. N. Engl. J. Med. 351 (2004) 1425-1436
39. Braun-Moscovici Y., Nahir A.M., and Balbir-Gurman A. Endothelin and pulmonary arterial hypertension. Sem Arthr Rheum 34 (2004) 442-453
40. Korn J.H., Mayes M., Matucci Cerinic M., Rainisio M., Pope J., Hachulla E., et al. Digital ulcers in systemic sclerosis. Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 50 (2004) 3985-3993
41. Ramos-Cazals M., Brito-Zeron P., Nardi N., Claver G., Risco G., Parraga F.D., et al. Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis. Rheumatol. 43 (2004) 1454-1456
42. Snyder M.J., Jacobs M.R., Grau R.G., Wilkes D.S., and Knox K.S. Resolution of severe digital ulceration during a course of bosentan therapy. Ann. Intern. Med. 142 (2005) 802-803
43. Humbert M., and Cabane J. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatol. 42 (2003) 191-193
44. Font J., Ramos-Cazals M., Nardi N., Brito-Zeron P., Aguilo S., and Belenguer R. One-year prospective follow-up of bosentan treatment for severe Raynaud's phenomenon associated with systemic sclerosis. Ann. Rheum. Dis. 64 III (2005) 278
45. Watanabe H., Ohashi K., Takeuski K., Yamashita K., Yokoyama T., Ttran Q., et al. Sildenafil for primary and secondary pulmonary hypertension. Clin. Pharmacol. Ther. 71 (2002) 398-402
46. Kumana C.R., Cheung G.T.Y., and Lau C.S. Severe digital ischaemia treated with phosphodiesterase inhibitors. Ann. Rheum. Dis. 63 (2004) 1522-1524
47. Rosenkranz S., Diet F., Karasch T., Weibrauch J., Wasserman K., and Erdman E. Sildanefil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the Raynaud phenomenon. Ann. Intern. Med. 139 (2003) 871-873
48. Kumar N., Allen J., Murray A., and Griffiths B. A pilot study assessing the response of a single dose of sildenafil citrate in the treatment of Raynaud's phenomenon in patients with systemic sclerosis. Rheumatol. 2 Suppl (2004) 97
49. Gore J., and Silver R. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Ann. Rheum. Dis. 64 (2005) 1387
50. Kamata Y., Kaminura T., Iwamoto M., and Minota S. Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis. Clin. Exp. Dermatol. 30 (2005) 451
51. Coleiro B., Marshall S.E., Denton C.P., Howell K., Blann A., Welsch K.J., et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatol. 40 (2001) 1038-1043
52. Dziadzio M., Denton C.P., Smith R., Howell K., Blann A., Bowers E., et al. Losartan therapy for Raynaud's phenomenon and scleroderma. Arthritis Rheum. 42 (1999) 2646-2655
53. Hirschi M., Katzenschlager R., Francesconi C., and Kundi M. Low level laser therapy in primary's Raynaud's phenomenon- Results of a placebo controlled double blind intervention study. J. Rheumatol. 31 (2004) 2408-2412
54. Matsumoto Y., Ueyama T., Endo M., Sasaki H., Kasashima F., Abe Y., et al. Endoscopic thoracic sympathicotomy for Raynaud's phenomenon. J. Vasc. Surg. 36 (2002) 57-61
55. Kotsis S.V., and Chung K.C. A systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia. J. Rheumatol. 30 (2003) 1788-1792